Scopio Founders Itai Hayut and Erez Na’aman (company pic)
Scopio Labs is an Israeli med-tech startup that develops Full-Field Digital Cell Morphology imaging and analysis platforms. The company raised $42 million in a Series D round of funding led by Fortissimo Capital. Scorpio has now raised $130 million to date.
Full-Field Digital Cell Morphology is a revolutionary approach to analyzing blood samples. Unlike traditional microscopy, which requires manual scanning of slides, this technology captures an entire blood smear in a single, high-resolution digital image. This comprehensive view allows for detailed examination of every cell, from the overall context to the minute cellular structures.
Founded in 2015 by two physicists CEO Itai Hayut and CTO Erez Naaman, Scopio Labs offers an advanced cell morphology platform that it says unlocks crucial diagnostic information through full-field scanning and the analysis of thousands of cells, for dramatically faster, earlier and more consistent and accurate detection and disease monitoring.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Scopio’s groundbreaking platform revolutionizes blood cell analysis through computational photography. By capturing full-field, high-resolution images of thousands of cells simultaneously, it eliminates the need for time-consuming manual microscopy. Integrated with AI-driven decision support, Scopio streamlines workflows, enabling rapid diagnosis, remote collaboration, and improved patient care. This innovative solution dramatically reduces costs and enhances diagnostic accuracy compared to traditional methods.
The firm’s Scopio X100 is a Full-Field Peripheral Blood Smear Application that is the first fully digital platform for small and medium labs that replaces the manual microscope. The Scopio X100HT was created for hematology labs with high throughput requirements. Scopio X100HT gives labs reliable and accelerated diagnostic capabilities.
“We are excited to have Fortissimo Capital lead our Series D funding round,” said Itai Hayut, Co-founder and CEO of Scopio Labs. “This investment is a testament to the remarkable progress we have made and the immense potential of our technology. With the support of Fortissimo Capital and our existing investors, we are well-positioned to revolutionize the field of hematology and deliver unparalleled value to our customers.”
